Tourniquet-Test in HHT

NCT06266624 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital, Essen

Phase

Not applicable

Started

2020-09-25

Last updated

2024-12-10

Condition(s) studied

HHT

Investigational drug(s) / intervention(s)

Tourniquet Test

Tourniquet Test: Tourniquet Test was performed in patients with HHT

Study summary

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * In patients with confirmed HHT diagnosis (≥ 3 Curaçao criteria or positive molecular genetics) * aged over 18 years Exclusion Criteria: * if inclusion criteria does not apply

Primary outcome measure(s)

number of positive Tourniquet Test results in HHT patients — three years
Documentation of the number of positive Tourniquet Test results in HHT patients

Trial sites (1)

Facility	City	Region	Status
University Hospital Essen	Essen	Nordrhein Westphalen

More University Hospital, Essen trials in Germany

Essen Coronary Artery Disease Registry Recruiting

Essen Amyloidosis Registry Recruiting

Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma Recruiting

Body Donation in HHT Recruiting

Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06266624 on ClinicalTrials.gov ↗ ← All trials in Germany